Wednesday, November 6, 2013

Human Factors Planning at DDP14 between Drug and Device Partners The drug delivery technologies market will reach $224.2 billion by 2017* with the need for self-administration and home healthcare devices driving this growth.

REALITY: The FDA evaluates the Human Factors of drug devices which are now necessary for approval. Patient adherence has a $300 billion impact on healthcare, according to the New England Healthcare Institute.

PLAN OF ACTION: Join us at IIR’s 18th Annual Drug Delivery Partnerships in Boca Raton, FL this January 27-29 to learn how to engineer devices that meet Human Factor requirements as well as how to choose technologies developed with these requirements in mind.

Here are some key sessions you will hear on Human Factors at DDP14: 

Sharing Responsibilities for Human Factors – Roles and Relationships of the Drug and Device Partners Lee Leichter, President, P/L Biomedical

Managing Human Factors and Clinical Bridging for Combination Product Post-Approval Changes Sherri Biondi, Associate Director, Device Development, Genentech

Scaling of Human Factor Engineering Development Efforts for New Designs and Platform Extensions Jim Kershner, Consultant Engineer, Human Factors/ Risk Management, Delivery Device Research & Development, Eli Lilly and Company

The Challenges and Best Practices for the Integration of Human Factors Engineering into Medical Device to Address Patients’ Unmet Needs Raza Ahmed, Worldwide Director, Medical Affairs, BD Medical – Pharmaceutical Systems, Self-Administration Injection Systems

To learn more, download the agenda.

Save $700 when you register by 11/15, use priority code XP1978LINK. If you have any questions about the agenda or event, please contact Kate Devery at or visit our webpage.

The Drug Delivery Partnerships International Team

Opt-in for updates
Follow us on Twitter
Visit our LinkedIn Page

No comments:

Post a Comment